Efficacy and safety of a low-dose 21-day combined oral contraceptive containing ethinylestradiol 20μg and drospirenone 3mg
D Cibula, U Karck, HG Weidenhammer, J Kunz… - Clinical drug …, 2006 - Springer
Objective: The purpose of this study was to assess the efficacy and safety of a new low-dose
oral contraceptive containing ethinylestradiol 20μg and drospirenone 3mg (EE 20μg/drsp …
oral contraceptive containing ethinylestradiol 20μg and drospirenone 3mg (EE 20μg/drsp …
Clinical findings with the oral contraceptive combination ethinylestradiol/dienogest in the Czech Republic.
S Golbs, R Domhardt, J Presl, M Ganev… - Methods and findings …, 2002 - europepmc.org
The efficacy and safety of the low dose monophasic oral contraceptive (OC) combination
containing 30 micrograms of ethinylestradiol (EE) and 2.0 mg of dienogest (DNG)(EE/DNG) …
containing 30 micrograms of ethinylestradiol (EE) and 2.0 mg of dienogest (DNG)(EE/DNG) …
Efficacy and safety of a novel oral contraceptive based on oestradiol (oestradiol valerate/dienogest): a Phase III trial
S Palacios, L Wildt, S Parke, A Machlitt, T Römer… - European Journal of …, 2010 - Elsevier
OBJECTIVE: A novel oral contraceptive (OC) that contains oestradiol valerate (E2V; 1mg of
E2V is equivalent to 0.76 mg of 17beta-oestradiol) and dienogest (DNG) has been …
E2V is equivalent to 0.76 mg of 17beta-oestradiol) and dienogest (DNG) has been …
New progestins—clinical experiences: gestodene
D Shoupe - American journal of obstetrics and gynecology, 1994 - Elsevier
Gestodene, one of three new gonane progestins, is the most potent on a per weight basis in
regard to progestational effects and has little or no estrogenic effect. In in vivo animal …
regard to progestational effects and has little or no estrogenic effect. In in vivo animal …
New progestogens in oral contraceptives
B Runnebaum, T Rabe - American Journal of Obstetrics and Gynecology, 1987 - Elsevier
The aim of using new synthetic progestogens (gestodene and norgestimate) in oral
hormonal contraceptives is to find a combination that has a more beneficial effect on …
hormonal contraceptives is to find a combination that has a more beneficial effect on …
Low dose contraceptive formulations: is further reduction in steroid dosage justified?
M Elstein - Advances in contraception, 1994 - Springer
Conclusions Low-dosage hormonal contraceptives could be reduced to contain 20 μg
ethinyl estradiol with the gonane progestogens. Available data demonstrate that …
ethinyl estradiol with the gonane progestogens. Available data demonstrate that …
Comparative profiles of reliability, cycle control and side effects of two oral contraceptive formulations containing 150 μg desogestrel and either 30 μg or 20 μg ethinyl …
M ÅKerlund, A Rødez… - BJOG: An International …, 1993 - Wiley Online Library
Objective To compare two oral contraceptive pills, both containing 150 μg desogestrel, but
with either 20 μg (Mercilon®) or 30 μg (Marvelon®/Desolett®) ethinyl oestradiol (EE) …
with either 20 μg (Mercilon®) or 30 μg (Marvelon®/Desolett®) ethinyl oestradiol (EE) …
A low-dose triphasic oral contraceptive
TB Woutersz, AJ Butler, M Cohen, VD Korba… - Fertility and sterility, 1987 - Elsevier
Controlled clinical investigations of a three-phase, low-dose oral contraceptive combination
of levonorgestrel and ethinyl estradiol were conducted at 17 sites in the United States and …
of levonorgestrel and ethinyl estradiol were conducted at 17 sites in the United States and …
Comparison of contraceptive acceptability of levonorgestrel and ethinyl oestradiol administered in one three-phasic (Trionetta®) and one monophasic (Neovletta®) …
L Carlborg - Contraception, 1983 - Elsevier
In a Swedish multicenter study, a total number of 835 women completed a total of 6472
treatment cycles. Half of them were allotted at random to use the monophasic oral …
treatment cycles. Half of them were allotted at random to use the monophasic oral …